Open Labelled, Randomized Study to Evaluate the Efficacy, Safety and Dose Selection of VM-1500A-LAI Drug in HIV-infected Patients Transferred From Previous Stable Therapy (NNRTI + 2NRTI), Including ELPIDA
Latest Information Update: 24 Dec 2021
Price :
$35 *
At a glance
- Drugs Deselsulfavirine (Primary) ; Elsulfavirine
- Indications HIV infections
- Focus Therapeutic Use
- Sponsors Viriom
- 17 Dec 2021 Status changed from recruiting to completed.
- 06 May 2020 New trial record
- 04 May 2020 According to a Viriom Inc media release, the Data Safety and Monitoring Board (DSMB) will select one of three dosing regimens assessed within this study for further development.